Screening of ATTRwt in Patient With Advanced AV-Block Undergoing Pacemaker Implantation (ATTRAB)

Steen Hvitfeldt Poulsen

Status: Enrolling

Conditions: Amyloid Cardiomyopathy; Block, AV

Treatments: Diagnostic Test: Amyloidosis screening (bloodtest, DPD-scintigraphy, potentially endomyocardial biopsy)

Study type: Observational

Funder types: Other

Identifiers

NCT05699044

1-10-72-53-22

Details and patient eligibility

About

The investigators will nationally investigate the prevalence of Transthyretin Amyloidosis wildtype (ATTRwt) in patients of ≥ 65 years with left ventricular hypertrophy who present with high degree atrioventricular block (AV-block) and are admitted for pacemaker implantation. The investigators aim to characterize the group of patients with positive screening of ATTR and compare the ATTRwt disease stage at time of diagnosis for patients identified with ATTR at screening with a control group of routinely clinically diagnosed ATTRwt patients.

Enrollment: 170 estimated patients

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men ≥65years or women ≥75years with unexplained AV-block with pacemaker indication, as decided per treating physician and presence of left ventricular hypertrophy ≥12mm.

Exclusion criteria

• Reversible causes for AV-block, som as AV-node disturbing medicament, ion-disturbances, hypothyroidism, hypoxia, ischemia, new heart surgery <1month, endocarditis.

Trial design

170 participants in 1 patient group

Amyloidosis Screening

Description:

Patients fulfilling eligibility criteria will screened for Cardiac Amyloidosis.

Treatment:

Diagnostic Test: Amyloidosis screening (bloodtest, DPD-scintigraphy, potentially endomyocardial biopsy)